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Clinical workflows for the non-invasive detection and characterization of disease states could benefit from 
optical-imaging biomarkers. In this Perspective, we discuss opportunities and challenges towards the clinical 
implementation of optical-imaging biomarkers for the early detection of cancer by analysing two case studies: 
the assessment of skin lesions in primary care, and the surveillance of patients with Barrett’s oesophagus in 
specialist care. We stress the importance of technical and biological validations and clinical-utility 
assessments, and the need to address implementation bottlenecks. In addition, we define a translational 
roadmap for the widespread clinical implementation of optical imaging-technologies. 
Optical-imaging biomarkers (OIBs), which rely on the interactions of tissue and non-ionizing optical radiation (with typical 
wavelengths in the range of 400–1,000 nm), can be used for the non-invasive detection and characterization of disease 
states. OIBs enable the real-time analysis of tissue biochemistry and the use of compact point-of-care and low-cost 
imaging devices (when compared to radiological imaging), and can operate across ranges of resolutions and depths 
spanning over four orders of magnitude1. 
Across the visible and near-infrared spectrum, light undergoes a range of complex interactions with tissue (Fig. 1). 
Conventional photographic methods that aim at replicating human vision2 discard most of the information obtained from 
these interactions and only capture reflected light across three channels (red, green and blue). Over the past decade, a 
wide range of promising OIBs that extract in-depth information provided by the different light–tissue interactions have 
emerged. However, for any new imaging biomarker to be deployed in a clinical setting, detailed validation is required. 
Technical validation defines the precision and accuracy with which the biomarker can be measured, whereas biological 
validation establishes the association between the biomarker and the underlying physiological, anatomical or 
pathological process. Clinical validation can then establish whether the biomarker does indeed identify, measure or 
predict the clinical outcome of interest. To achieve clinical validation, the imaging device needs to conform to clinical 
performance and safety specifications, and be approved for use in patients. 
With standard radiological imaging — such as computed tomography (CT) or magnetic resonance imaging (MRI) — the 
imaging device required to measure a novel imaging biomarker is already clinically approved for use in humans and 
widely available across radiology departments3. In contrast, for OIBs it is uncommon that a clinically approved imaging 
device (alongside its associated specialist data-acquisition and data-interpretation methods) is available for clinical 
validation. Therefore, biological validation may be restricted to testing ex vivo samples such as histopathological 
sections. Compared to the in vivo setting, these can be prone to bias, and generate a different range of optical 
interactions, ultimately resulting in misleading conclusions as to the potential clinical utility of the OIB (ref. 4,5). 
Furthermore, OIBs may be deployed in a range of settings during the patient-management pathway, spanning primary 
care (such as a family physician) and specialist care (specialist practice, referral, or medical centre). Hence, even a well-
defined OIB with promising performance in an experimental setting may not receive approval if it fails to adequately 
address the specific diagnostic question at a defined point in the patient-management pathway. 
Given the promise of emerging OIBs, in this Perspective we discuss challenges and opportunities for their clinical 
translation, from development to implementation in healthcare systems. To this end, we selected two distinct case 
studies in early cancer detection, and identified a number of OIBs that have reached maturity in clinical use (Table 1). 
The first case study covers primary care in the context of the assessment of melanocytic skin lesions, and the second 
case study covers specialist care in the context of the surveillance of patients with Barrett’s oesophagus. We use trends 
identified from both cases to define a set of translational characteristics that contribute to the likelihood of a new OIB 
being incorporated into healthcare, accelerating translation during both technical and biological validation through to the 
assessment of clinical utility. Taking a page from the recent consensus roadmap for radiological imaging biomarkers3, we 
propose an OIB roadmap that links the translational characteristics of OIBs and defines the key bottlenecks that must be 
overcome in order to facilitate a smoother path for their clinical translation. 
 
Early detection of melanoma in primary care 
Although malignant melanoma represents less than 5% of cutaneous malignancies, it causes the majority of skin-cancer 
deaths6. In the United Kingdom, the current management of patients presenting with a pigmented skin lesion involves a 
primary-care general practitioner assessing the patient’s history and performing a naked-eye visual inspection of the 
lesion, guided by a seven-point checklist: lesion size (diameter larger than 7 mm), change in lesion size, and the 
presence of irregular pigmentation, of an irregular border, of inflammation, of itch or altered sensation, and of oozing or 
crusting of the lesion. If the lesion appears suspicious on the basis of this visual assessment, the patient is referred to 
specialist care via an urgent skin-cancer pathway7. 
	
The potential benefit that population-screening programmes could have in malignant melanoma management is 
evidenced by the improved survival of patients for whom melanomas are detected by physicians rather than by patients 
or family members8. This occurs because lesion thickness is a key determinant of patient outcome (the five-year survival 
rate improves to 91% for lesions smaller than 1-mm thick from a mere 46% for lesions larger than 4-mm thick9), and 
because physicians can typically recognize thinner lesions. A large population study suggested that an almost 50% 
reduction in mortality rates is possible by adopting full-body skin examinations performed by dermatologists10,11. 
However, owing to methodological limitations of the study12, it did not provide sufficient evidence to recommend a 
national population screening programme. 
Because the skin provides an easily accessible surface for optical imaging, OIBs can improve the triage of suspected 
malignant melanoma in primary care, and provide sensitivity and specificity for diagnosis in specialist care, thus avoiding 
unnecessary biopsies when possible. Optical-imaging approaches can be broadly categorized as methods that enable 
the visualization of the tissue with spatial resolution (imaging), and methods that map point-based biochemical 
information (spectroscopy). A few multispectral-imaging techniques are, however, capable of combining both types of 
information. In what follows, we review devices that have received regulatory approval for use in humans in each of 
these categories. 
Imaging. Dermatologists use a handheld dermoscope (a magnifying optical-imaging instrument) in about 78% of 
examinations of suspected malignant melanoma (ref. 13). According to a meta-analysis of 8,487 suspicious skin lesions, 
a dermoscope improves the detection sensitivity from 71% to 90% and the specificity from 81% to 90% (ref. 14) with 
respect to examination solely by the naked eye. Multispectral-imaging methods employ handheld devices to illuminate 
the tissue with broadband white light, and measure the reflected light at several different wavelengths (typically, up to 
ten). The resulting spectral images are then processed, often using reference spectral properties of prominent tissue 
absorbers, such as melanin, haemoglobin, water and lipids. For example, SIAscopy (MedX, Canada) measures the 
reflected light of the skin at eight different wavelengths. The data are then used to generate maps of melanin, dermal 
melanin, haemoglobin and collagen in the skin using model-based fitting15. The MoleMate system (MedX, Canada) 
combines SIAscopy with a primary-care scoring algorithm. The algorithm interprets these maps and classifies lesions as 
‘suspicious’, ‘not suspicious’, ‘haemangioma’, or ‘seborrheic keratosis’16. A large primary-care randomized controlled 
trial17 of the MoleMate system in the United Kingdom showed that incorporating the use of the device into existing best-
practice clinical guidelines (including the seven-point checklist) led to similar diagnostic accuracy for ‘suspicious’ lesions 
as that of current practice18. Furthermore, clinicians and patients rated the device more highly for ‘reassuring and 
thorough care’18. However, as its use resulted in more referrals from primary care, it was not recommended for use in 
routine primary care. 
Two additional multispectral-imaging methods have been examined for the inspection of malignant melanoma. SkinSpect 
(Spectral Molecular Imaging, USA) produces melanin and haemoglobin maps similar to those of MoleMate19–22 also 
using model-based fitting, so it may be possible to include SkinSpect into established scoring algorithms. MelaFind 
(Strata Skin Science, USA; formerly Mela Science), which has been discontinued, took a different approach. Instead of 
using automatic segmentation, it performs feature extraction and classification23 to translate the multispectral-imaging 
data into a binary biomarker classification: ‘biopsy’ or ‘no-biopsy’24. In a study comparing German and United States 
dermatologists, German dermatologists were less likely to incorporate MelaFind into their decision-making. It was 
suggested that the German physicians’ older age, more extensive dermoscopy training, and unfamiliarity with MelaFind 
(ref. 25) contributed to the less-frequent use of the technology, thus indicating that MelaFind may find a niche in assisting 
less-experienced dermatologists or those without training in dermoscopy. Despite the widespread availability of 
multispectral-imaging methods for the assessment of suspected malignant melanoma, none of these methods have been 
incorporated into routine use or into decision-making algorithms. 
Reflectance confocal microscopy (RCM) captures high-resolution images of the epidermis and papillary dermis with 
almost cellular resolution26. These images are interpreted via a feature-based scoring algorithm that classifies a binary 
biomarker: ‘non-MM’ and ‘MM‘(ref. 27). RCM has been implemented in the VivaScope imaging systems (Caliber I.D., 
USA), which were found to significantly increase specificity when compared to dermoscopy in a recent meta-analysis26 of 
eight studies28–35. However, national authorities such as NICE in the UK do not recommend its use because of 
insufficient evidence of a clinically relevant advance36. High-resolution images can also be obtained with DermaInspect 
(Jenlab, Germany), a multiphoton-tomography–fluorescence-lifetime-imaging device that measures time-resolved tissue 
autofluorescence37,38 to detect metabolic and structural molecules in tissue. In comparison to simple handheld devices 
conventionally used by dermatologists, the device is much larger and more expensive. Preliminary results for diagnosing 
malignant melanoma using DermaInspect are promising39, but further studies in larger patient cohorts are needed to 
evaluate whether DermaInspect can improve the sensitivity or specificity for the diagnosis of malignant melanoma. 
Optical coherence tomography (OCT) captures high-resolution cross-sectional images of the skin by a method that is 
similar to ultrasound40. Compared to dermoscopy or confocal techniques, OCT enables the imaging of skin layers deeper 
than 1 mm. Pilot studies have demonstrated the potential of OCT for the detection of malignant melanoma41,42. Two 
devices are currently in clinical use with similar technical specifications43: Skintell (Agfa Healthcare, Belgium and 
Germany) and Vivosight (Michelson Diagnostics, UK). Since cross-sectional OCT images are similar to histological 
images, and en-face OCT images are similar to confocal-microscopy images, OCT is able to use feature descriptors 
from pathologists, including architectural patterns and cytological features of pigmented cells in the epidermis, dermo-
epidermal junction and dermis, providing a starting point for feature-based algorithms for disease classification and 
biomarker development41. The widespread adoption of OCT in ophthalmology44,45 may contribute to the successful 
application of OCT in the diagnosis of malignant melanoma, but additional clinical trials are needed to evaluate whether 
there is sufficient added value in depth-resolved OCT images. 
	
Spectroscopy. In spectroscopy methods, the tissue is illuminated, and changes in wavelength or intensity that result 
from light absorption, light scattering or fluorescence interactions of light and tissue46,47 are measured. These methods 
differentiate malignant from benign tissue on the basis of the properties of the bulk chemical constituents of tissue — 
such as water, lipids, proteins, RNA, DNA, haemoglobin and melanin — or of specific structural (in particular, collagen) 
or metabolic (such as NADH) molecules46,47. Spectroscopy-based modalities are typically limited to a narrow field of view 
or to even mapping with a single point, yet acquire data at high spectral resolution (often measuring the intensity at 
hundreds or thousands of different wavelengths). The high dimensionality of spectral data prohibits interpretation by the 
human eye, so this data is usually analysed via multivariate statistical techniques, or increasingly by machine-learning 
approaches, to reach a binary biomarker classification, with histopathology providing the ground truth for training these 
algorithms48. Perhaps owing to the complexity of the data, most spectroscopy methods remain firmly in the preclinical 
phase and have not achieved regulatory approval49,50,59,51–58. 
Raman spectroscopy is one optical-spectroscopy modality that has received regulatory approval. It probes the primary 
chemical constituents of tissue via inelastic scattering. The acquired spectra are classified using principal component 
analysis and discriminant analysis, both based on a training set of known spectra for which the classifications are known 
a priori. Several large clinical studies have demonstrated the potential of Raman spectroscopy in skin imaging. One of 
these studies55 has resulted in a commercial clinical system (Aura; Verisante, Canada; ref. 61) that has received 
regulatory approval. Nonetheless, despite over two decades of research, Raman spectroscopy is not routinely used in 
the clinic for the evaluation of malignant melanoma. The slow uptake might be due to challenges in obtaining an accurate 
ground truth for training the classifiers60,61, and to challenges of quality assurance and control in spectral calibration and 
spectra interpretation48. Recent developments have significantly shortened the signal acquisition times (<1 s in 
endoscopy), which may solve some of these problems by allowing faster and more robust signal acquisition from tissues 
that are inherently heterogeneous, allowing for better delineation of the rich spectral features enabled by this imaging 
modality. 
Considerations for technology adoption in primary care. One key to improving the outcomes of malignant melanoma 
will be earlier disease detection. To achieve this, detection methods have to minimize false-negative rates and be easily 
implementable while maintaining a high negative predictive value. Afterwards, cost-effectiveness can be considered, via 
an evaluation of the entire impact of the technology with regards to complete patient management. 
Another matter is whether primary-care physicians are willing to use new imaging methods. Although there is little doubt 
as to whether microscopic tools such as RCM provide better information than macroscopic imaging systems (and then 
naked-eye examination), the added time required to image entire macroscopic fields of view, or to choose which 
microscopic fields to image, is a challenge for the adoption of imaging technology in primary care. Methods for 
automated mosaicking with microscopy hold substantial promise to improve this, but the logistical problem of mapping 
out a macroscopic field of view with a microscopic tool is one that may need to be solved in order to facilitate wide 
adoption of the technology. 
 
Early detection of dysplasia in Barrett’s oesophagus 
Barrett’s Oesophagus (BO) is an acquired condition in which columnar epithelium replaces the stratified squamous 
epithelium of the distal oesophagus. Patients with BO have an elevated risk of developing oesophageal 
adenocarcinoma62,63, which increases in the presence of dysplasia64,65. As a result, patients with BO are often 
recommended to undergo routine surveillance with high-definition white light endoscopy (HD-WLE) on a three-to-five 
year basis66–70. Targeted and random biopsies are taken during endoscopy, and analysed by a pathologist for the 
identification of cellular changes associated with dysplasia. 
Although several studies have shown that a surveillance regime detects cancers at an earlier stage and increases 
survival71–75, its sensitivity remains as low as 40% (ref. 76), thus resulting in a high rate of missed dysplastic lesions77. 
The main reasons for the low sensitivity are that dysplasia can be difficult to spot on HD-WLE (ref. 67) and that taking 
random biopsies is time consuming, costly, and prone to sampling errors67. New developments in optical imaging for 
addressing these limitations fall into two main categories: advances in wide-field imaging aim to provide better 
visualisation of dysplasia and to provide a ‘red flag’ for the endoscopist to target the biopsy; and advances in narrow-field 
imaging provide an ‘optical biopsy’ of the suspicious areas that could ultimately reduce or replace tissue biopsy. The 
combination of a high sensitivity ‘red flag’ approach with a high specificity ‘optical biopsy’ approach may prove to be a 
useful strategy in endoscopic imaging for BO (and for other cancers in the GI tract). According to the guidelines of the 
American Society for Gastrointestinal Endoscopy (ASGE), a new technology needs to have 90% sensitivity, 80% 
specificity and 98% negative predictive value to be recommended for targeted biopsy78. To date, only three technologies 
have met these thresholds: narrow band imaging (NBI), acetic acid chromoendoscopy and endoscope-based confocal 
laser endomicroscopy (eCLE). 
Wide-field imaging. In chromoendoscopy, dyes are applied to enhance the contrast in tissues so as to improve the 
detection of early lesions. The most common dyes are methylene blue79,80 (a vital stain that is absorbed by the tissue) 
and acetic acid77,81,82 (a weak acid that causes a transient whitening of the tissue and accentuates the mucosal pit 
pattern). The optical biomarker in these cases is the presence or absence of a pattern of dye staining, which is normally 
agreed by expert consensus. Although chromoendoscopy helps to visualise the tissue structure without the need for 
specialized equipment, the application of the dye requires additional tissue preparation, adding time and costs to the 
procedure, which is not widely reimbursed5. Chromoendoscopy using acetic acid has been clinically recommended to 
increase the yield of targeted biopsy5, but for methylene blue phototoxicity concerns remain83–85. Numerous research 
groups are developing targeted optical molecular-imaging dyes that enable the visualisation of complex biochemical 
processes involved in disease86,87. These dyes bind disease-specific cell-surface receptors or detect other disease-
	
specific molecular changes, revealing particular pathologies as regions of altered fluorescence. As with traditional 
chromoendoscopy, the use of these dyes would increase the time and cost of an endoscopy procedure; furthermore, the 
cost of synthesising new targeted dyes at clinical grade and of performing clinical trials to prove efficacy can be 
prohibitive. Thus, despite promising results88–91, a convincing demonstration of a significant improvement in clinical 
performance is still required to justify the added complexity of using optical molecular imaging in routine endoscopic 
surveillance. 
To avoid the need for dyes, virtual (or electronic) chromoendoscopy (VC) can be employed to enhance the contrast by 
illuminating the tissue via restricted bandwidths of light, as in narrow-band imaging (NBI, Olympus) and blue-laser 
imaging (BLI, Fuji)92,93. Alternatively, post-processing software can be used to enhance the images, as in intelligent 
colour enhancement (FICE, Fuij)94 and iSCAN (Pentax)95. Post-processing software has been shown to be equivalent or 
superior to HD-WLE or NBI in several gastrointestinal indications96–105, with reasonable inter-observer agreement106,107. 
VC requires only minor hardware or software modifications to the standard endoscopy equipment and does not require 
any dye that could create toxicology concerns. Hence, VC has received regulatory approval and is widely available. NBI 
using a feature-based classification108 has also met the ASGE threshold for clinical recommendation in targeting biopsy5. 
Exploiting a different contrast mechanism, autofluorescence imaging (AFI) relies on the intrinsic fluorescence emission of 
structural (such as collagen) and metabolic (such as NADH) molecules in tissue109 to detect dysplasia as dark purple 
patches of reduced AFI signal110. Although AFI initially showed promising results, its low specificity110 prevented it from 
replacing WLE in the clinic. Instead, AFI has been combined with HD-WLE and VC in standard commercial forward-
facing endoscopes to create trimodal imaging systems111–113. 
Endomicroscopy and spectroscopy. Once suspicious areas have been identified via wide-field imaging, a tissue 
biopsy is taken for histopathological analysis. Given the time and cost required for pathological assessments, several 
high-resolution endoscopy (or endomicroscopy) modalities have been developed with the goal of replacing tissue 
biopsies with in situ optical biopsies. In these approaches, high-resolution images of the epithelium are captured and 
interpreted using a set of consensus-feature-based criteria to classify pathological states114,115. Usually, an exogenous 
contrast agent, such as fluorescein, is added to enhance the contrast. 
Owing to the need for confocal laser excitation and image collection optics, confocal laser endomicroscopy (CLE) is 
performed over a narrow field of view by introducing a probe into the accessory channel of a standard endoscopy (probe-
based, pCLE) or by replacing the standard endoscope with a standalone endomicroscope (eCLE). pCLE has the 
advantage of being compatible to the standard endoscopy procedure and has received regulatory approval (Cellvizio, 
Mauna Kea). eCLE (FIVE 1, Optiscan; ISC 1000, Pentax) has also received regulatory approval and meets the 
standards for use in targeting biopsy, but is no longer commercially available. 
Volumetric optical coherence tomography (vOCT, also known as volumetric laser endomicroscopy, VLE) is an alternative 
endomicroscopy technique able to capture high-resolution depth-resolved cross-sectional images of the entire distal 
oesophagus116–118 through a balloon-based system (NVisionVLE, Ninepoint Medical)119–123. As with pCLE, the balloon is 
introduced via the working channel of a standard endoscope. vOCT images have been shown to correlate with 
histological images124–126 and can be interpreted by a trained image interpreter using a set of feature-based criteria to 
perform disease classification127. However, the dissimilarity between cross-sectional OCT images and standard HD-WLE 
image limits their co-registration and makes it challenging for endoscopists to re-locate suspicious areas identified on 
OCT for WLE-guided intervention. Cautery marking is currently being investigated to solve this problem128. A further 
consequence of the lack of familiarity of the cross-sectional OCT images is the need for advanced training of expert 
image interpreters, although it is possible for these experts to identify dysplasia129 with good inter-observer agreement127. 
Another barrier that limits widespread translation is that manual image analysis takes several hours. In this regard, 
automated segmentation algorithms may help130. Automated algorithms may also be combined with the emerging 
tethered capsule OCT endoscopy systems117 that can be swallowed un-sedated under the supervision of a nurse in 
primary care131. As cross-sectional information is particularly important in the assessment of submucosal invasions when 
staging oesophageal adenocarcinoma, further developments to improve imaging at depth, for example, by using 
photoacoustic imaging132, are still needed. 
In addition to endomicroscopy imaging, Raman spectroscopy has been applied endoscopically to obtain biochemical 
information of the tissue so as to distinguish dysplasia from surrounding Barrett’s tissue on the basis of least-squares 
discriminant analysis of the Raman spectra. But low reproducibility, expensive equipment, and the need for long 
integration times, have limited clinical translation. However, recent improvements in integration times133,134 and in 
classification algorithms to provide the endoscopist with auditory feedback of a diagnosis in real time (0.2 seconds) led to 
in vivo trials133. Larger-scale in vivo trials and calibration methods will be needed to improve reproducibility and to ensure 
that promising ex vivo results apply in vivo60. 
Considerations for technology adoption in specialist care. In primary care the consequences of false negatives are 
particularly acute, since no further follow up will be provided to the patient. In specialist care, however, the number of 
patients is lower than in primary care, and the trade-off between acceptable levels of false-positive and false-negative 
results depends on the next step of disease management. Ideally, both should be minimized. As such, the cutting edge 
of new technology is often found in specialist care, where novel techniques could add value to the decision-making 
process. Defining the value added of a given technology requires rigorous testing for diagnostic accuracy, acceptability, 
effectiveness and cost-effectiveness in the intended setting, by using case-controlled, randomized, and double-blinded 
clinical trials so as to assess the technology’s real value to the healthcare system. If the diagnosis is more accurate or 
the amount of time a specialist is required is reduced, then the technology may add value. Regulatory approvals for 
devices, particularly with predicates, often lack clinical evidence from such trials135, so it is common for approved 
technologies to fail to achieve widespread adoption, because they do not change clinical practice. [Recent changes] 
[https://eur-lex.europa.eu/legal-content/ENG/TXT/PDF/?uri=CELEX:32017R0745] to the EU medical device legislative 
	
framework may mitigate this challenge in the future. Thus, the development pipeline of optical imaging devices and their 
associated OIBs continues well beyond regulatory approval. Most commonly, consensus studies from specialist societies 
are required to reach the recommendation for use in routine patient management. 
 
Translational characteristics of successful OIBs 
The two case studies discussed reveal a wide range of promising optical methods that have been established in a 
research setting and that could potentially improve early cancer detection. However, few of these methods have 
successfully received regulatory approval, and even fewer have progressed to recommendation in healthcare systems.  
Cost-effectiveness is a key consideration for adoption into healthcare systems, and it applies to one-off costs (such as 
the purchase of instrumentation and the training of operators and interpreters) and to ongoing costs (such as the 
employment of operators, image interpreters and support staff, the purchase of disposable materials, cleaning or 
sterilization, and annual maintenance). In private healthcare systems, the development of new reimbursement codes can 
promote translation, as it has been the case with OCT in the context of opthalmology136. Ultimately, acceptable costs 
would be determined on the basis of the overall performance of the OIB and whether it increases quality-adjusted life 
years (QALYs) or it reduces other healthcare costs. Examples of healthcare costs that could be alleviated with 
successful translation of a new OIB for early cancer detection include those costs associated with treating more 
advanced disease (approximately a further £10,000 per patient for late-stage colorectal cancer with respect to patients 
with the early stage of the disease137) or those associated with exhaustive physical biopsies (for example, targeting 
biopsies in BO surveillance can reduce per-patient biopsy costs in the UK from approximately £1,000 to £30; ref. 77; such 
costs considerably depend on country). Assessments of OIB cost-effectiveness should therefore be made in light of the 
intended diagnostic indication and of the potential change in the current clinical patient pathway that could be achieved. 
Having achieved cost-effectiveness, OIBs still face a wide range of hurdles in clinical translation. In reviewing the two 
case studies, we identified several translational characteristics that are common among widely-adopted OIBs. Most of 
the identified translational characteristics fall into three main categories: device and methodology, image acquisition and 
handling, and image interpretation. These separate technical aspects of the optical-imaging modality (detailed below 
together with suggestions for how to best achieve clinical translation) from biomarker measurements and image analysis. 
Contrast mechanism underlying the OIB. Exploiting endogenous contrast (imaging without application of dyes) to 
detect the OIB is favourable for a clinical application, although exogenous contrast agents can improve the contrast of 
cancer tissue compared to healthy tissue, both as non-specific stains138 and as targeted molecular-imaging agents86. 
However, contrast agents require synthesis with good manufacturing practice (GMP) standards, toxicology studies, 
specific instrumentation, and additional procedure time and cost76,139. Several aspects of contrast-agent chemistry 
increase the likelihood of their successful clinical translation: having a validated target (structural or molecular) increases 
confidence in the reproducibility of the results; administering agents topically rather than intravenously limits agent 
exposure to the tissue of interest and speeds up procedures; and using formulations of agents with long-term stability is 
favourable. 
Instrumentation for OIB measurement. If a new device is required to measure the OIB, the device must be approved 
by regulatory bodies such as the FDA (refs. 135,140–142). For clinical implementation, compact, robust and transportable 
optical-imaging devices are highly desirable and more likely to succeed in clinical translation, while complex or delicate 
optics are less amenable to clinical implementation. Furthermore, devices that are compatible with existing systems, or 
that include current standard-of-care methods for reference, are more likely to reach deployment in healthcare systems, 
as they do not require a complete overhaul of existing equipment and facilities. The compatibility with current systems 
also facilitates head-to-head trials and allows a modality to be introduced to the clinic as an adjunct to an existing 
modality. Compatibility with the existing clinical workflow, and the avoidance of major changes to procedure times or 
costs, are additional advantages. 
Device operator expertise. The potential operators of optical instruments for measuring OIBs may be lay people, 
professionals working in primary care, or highly specialized individuals working in a specialist care centre. If a new 
approach gives similar clinical results to an existing approach, yet requires less expertise, the likelihood of clinical 
translation is higher. Furthermore, if the need for training is sufficiently reduced, the approach may be translated from an 
expert to a generalist setting, reducing the burden on specialist care centres and the cost of running a high-volume 
imaging suite117. Conversely, if a high level of specialist knowledge is required to measure an OIB compared to the 
existing standard-of-care, the OIB is unlikely to be widely adopted, unless evidence can be provided that it contributes to 
improved clinical outcomes. Excessive complexity in the name of additional device performance may deter clinical 
adoption143. Clear standard operating procedures should be determined and adhered to improve ‘ease of use’ for 
operators and the increase likelihood of translation. 
Some devices may be clinically translated because they reassure patients and clinicians of improved outcomes, whether 
or not they actually improve the outcome. One example is the MoleMate skin-imaging system, which despite not being 
more accurate than best practice for detecting melanoma, it reassured patients and clinicians that they were receiving or 
providing thorough care18. 
OIB interpreter expertise. Converting the raw-image data acquired using the optical modality into clinically relevant OIB 
information involves establishing image-interpretation criteria needed to deliver high sensitivity, specificity, inter-
interpreter agreement and short training times. Criteria can include a binary decision, a library-based classification, the 
presence of specific image patterns108,144, or a change in signal intensity relative to a defined threshold. Several caveats 
can complicate this process. For example, increased expertise does not necessarily imply better inter-interpreter 
agreement145,146, and when applied to videos147 the criteria often result in lower performance than originally reported in 
	
still-image interpretation148–150. Establishing these OIBs is a time-consuming task, often requiring international consensus 
across multiple centres after regulatory approval of a device. Determining their clinical performance then requires 
randomized controlled trials in the appropriate settings, which are expensive and difficult to implement in a diagnostic 
setting for screening and surveillance programmes. For more complex biomarkers, expert image interpreters need to be 
trained, which further adds to the cost and time for adoption and makes the biomarker difficult to standardize across 
centres. Simplifying the output of the biomarker or transforming it to familiar images reduces the need for retraining, may 
enable non-experts to make diagnoses, and may smooth the translational pathway. 
Automated analysis that provides clear feedback to the interpreter of the biomarker can minimize the need for expert 
image interpreters. For many optical-imaging approaches, data reduction is essential because the dimensionality of the 
data is beyond interpretation by the human image interpreter. It has the potential to be objective, standardized and 
cheaper than employing human expertise, but has yet to mature to a stage where it is fully capable of operating in real 
time with sufficient performance to replace the human image interpreter151,152. If the technology is to be adopted in 
primary care, it will be important to use the device in a way that provides expert-level diagnostics with a high negative 
predictive value. 
Repeatability and reproducibility of OIB measurements. Both repeatability and reproducibility across devices, 
operators and image interpreters must be assessed to evaluate the achievable precision for the measurement of the 
OIB. Although inter-analyst agreement (encompassing operators and image interpreters) is often assessed, intra-analyst, 
intra-device, and inter-device variabilities are often overlooked, making the comparative evaluation of OIBs challenging. 
To maximize the opportunity for translation to the intended setting, studies should be designed to enable the comparison 
of results obtained across multiple centres. 
Co-registration of OIB information. The spatially resolved information obtained via imaging is often useful during a 
later surgical procedure for guiding tumour resection. However, optical-imaging modalities do not always provide 
sufficient anatomical information to guide an intervention. Strategies to overcome this (with increasing levels of 
complexity that could hinder translation) are co-registration with an existing modality that is compatible with surgical 
treatment153, application of laser cautery marks to highlight target areas128, and projection of the image data onto the 
patient or into the surgeon’s field of view via augmented-reality technology154,155. 
The aforementioned wide-field endoscopy techniques produce 2D images that are easily integrated into standard 
equipment for HD-WLE, facilitating the widespread uptake of OIBs in endoscopy (compared to dermoscopy-based 
approaches66,111,113,156). Acetic acid chromoendoscopy and NBI were recently reported to meet the thresholds required 
for recommendation5, and this milestone was achieved in part because of their deployment at many sites internationally, 
enabling the extensive development of image-classification criteria and publication of consensus statements108,148–
150,157,158. 
 
A roadmap for OIBs 
We have formulated an OIB roadmap (Fig. 2), adapted from the international consensus ‘Imaging Biomarker Roadmap’ 
created for use in cancer studies3. Domain 1, ‘Discovery’, may be driven by a ‘technology push’, where an existing 
imaging technology is applied to an unmet clinical need, or by a ‘clinical pull’, where the OIB and/or technology are 
developed in response to a clearly defined unmet clinical need159. 
In all domains, optical-device development plays a larger role in translation than in standard radiological imaging, where 
a device to measure the imaging biomarker is usually already clinically approved. The OIB roadmap further emphasizes 
the concurrency of technical and biological validation. Technical validation seeks to define the precision and accuracy 
with which a given OIB can be measured, whereas biological and clinical validation seek to connect the OIB with 
underlying pathological processes and define clinical-performance characteristics such as negative predictive value or 
specificity. Throughout the OIB roadmap, there is a complex interplay of limitations imposed by the device, the contrast 
mechanism and the OIB definition, meaning that technical and biological validation cannot be considered in isolation. For 
example, the precision (repeatability and reproducibility) of measuring a given OIB defined with respect to a perfect test 
target will differ considerably from the precision defined with respect to a biological measurement made in a patient, 
which is directly relevant in the clinical application. 
The OIB roadmap emphasizes the feedback loops that often inhibit translation, and highlights the key translational 
characteristics that can be exploited to accelerate translation. Also, our case studies revealed five key translational 
barriers that need to be addressed to facilitate a smoother path to clinical translation. We discuss each of them in the 
following subsections. 
Lack of defined safe exposure limits for diagnostics. Safe and effective illumination levels that allow accurate 
measurement of a given biomarker must be established before in vivo trials take place. Visible and near-infrared light is 
not ionizing, but can lead to thermal damage, photosensitization and photoallergic reactions under certain conditions160. 
Molecularly damaging radiation extends further towards the visible spectrum161. The published guidelines for optical-
radiation exposure limits only concern the retina and skin and are limited in their application to workers rather than 
patients, which presents a challenge for those using incoherent light and internal diagnostic-imaging devices160,162. 
Rather, safety for internal exposure is defined in terms of thermal and photobiological consequences, with the 
assumption that the gastrointestinal tract and skin respond similarly. There is an unmet need for experimentally validated 
exposure limits for tissues beyond the retina and the skin, so that safe patient exposures for optical imaging can be 
clearly defined. This would also address frequently raised concerns by ethical review boards of clinical trials. Access to 
advisors of optical-radiation protection with training in clinical optical imaging would increase the understanding of the 
capabilities, strengths and weaknesses of optical-imaging systems and their biomarkers. 
	
Lack of standardized quality assurance. The uncertainty regarding optical-exposure limits is illustrative of a more 
general lack of standardization in optical imaging. Defining the performance of a device at the point of manufacture and 
throughout lifetime is crucial for comparing different devices (by measuring the same source of optical contrast) and for 
debugging device-specific problems. 
Whilst performance standards (documents that suggest relevant performance characteristics and test methods) exist for 
the established non-optical imaging methods, such as the NEMA (National Electrical Manufacturers Association) imaging 
standards for positron emission tomography (PET)163, optical imaging currently lacks published standards140. As a result, 
optical-imaging contrast agents and devices must often be approved in tandem. This doesn’t occur with PET, for which 
contrast agents are usually approved for use in a range of devices (and PET devices can also be approved for use with a 
range of contrast agents), because sufficient evidence supporting similarities across devices exists140. Unfortunately, the 
consequence for optical imaging is that healthcare providers must purchase specific devices when working with specific 
optical-imaging agents, resulting in prohibitive costs and hindering the translation of new contrast agents. 
In the United States and Europe, medical devices may be approved based on similarity to a predicate device, gaining 
510(k) clearance in the United States and CE marking in the European Union (ref. 135). Yet without standardization, the 
similarity to a predicate device may be difficult to define. With imaging standards, device performance could be 
compared to an appropriate standard, allowing inferiority to be spotted at an earlier stage in the translational roadmap. 
Additionally, if device-performance standards were established it would help separate device approval from agent 
approval in cases where exogenous agents are being imaged. 
Calibration standards exist for all standard diagnostic imaging tests164. Stable luminescent phantoms, calibrated to the 
International System of Units unit of radiance, with an effective shelf life of more than two years, have now been 
developed to assess some optical diagnostic-imaging tests based on reflectance and fluorescence imaging165. Future 
work in other modalities, such as OCT and photoacoustic imaging, should aim to create similar standards for assessing 
intra-device and inter-device variabilities, thus helping to achieve improved repeatability and reproducibility for 
multicentre use. 
Lack of validated representative ex vivo models. When tissue is excised from the body, several OIBs change 
irreversibly. For example, the lack of active blood flow changes the spectrum of tissue by reducing blood oxygenation to 
0%, which consequently alters the haemoglobin absorption spectrum. Furthermore, tissue autofluorescence can be 
modified upon exposure to ambient light, and the tissue structure may be distorted by surgical trauma or by positioning 
the tissue on a rigid surface. Ultimately, tissues will degrade unless they are frozen or fixed, which further alters tissue 
properties60. The gap between data acquired with ex vivo imaging and data acquired with in vivo imaging is therefore 
large, and data acquired from ex vivo tissues may contain insurmountable artefacts if the tissues are not properly 
handled. 
Challenges with using ex vivo tissue for validation raise the need for new model systems, which may arise through 
improved tissue-mimicking phantoms, or from bioengineered tissues. Whichever route is chosen, to avoid disappointing 
in vivo results later in the roadmap, it is crucial to ensure that the ex vivo model is as representative as possible of the in 
vivo situation. For example, modalities that are sensitive to blood oxygenation should never use excised tissue for 
validation unless it is perfused, modalities sensitive to preparation artefacts should avoid chemically fixed or frozen 
tissue60, and dyes that incorporate labelled human antibodies should use models that try to replicate human biology, 
such as human-derived tumour xenografts, rather than animal tumour models where the binding affinity may be different. 
Lack of accurate and validated clinical gold-standards. The clinical gold-standards used as comparators for 
evaluating the diagnostic accuracy, sensitivity and specificity of new OIBs must be well validated. Most commonly, gold-
standard diagnosis is determined via the assessment of stained tissue sections by a pathologist. To achieve the most 
accurate gold standard for validation of OIBs, consensus of several independent pathologists is needed, as they are not 
always in agreement166. In the best-case scenario, only unanimous decisions would be accepted, although this is difficult 
to achieve in practice as it significantly decreases the number of samples that can be incorporated into any performance 
analysis. In practice, decision algorithms are used to combine contrasting histologic diagnoses of several pathologists to 
reach a single final diagnosis24. In future, machine-learning algorithms trained on huge datasets may be able to provide 
an objective diagnosis, but this is still some way from being realized. Another confounding factor is the transition from a 
biopsy read to in vivo imaging, which requires an appreciation of nuances associated with the fact that a sample of tissue 
is typically a mix of pathological and healthy tissue. Each optical imaging pixel could include contributions from one or 
more tissue states. Validating imaging tools in vivo thus requires high congruence in spatial alignment between the in 
vivo and ex vivo coordinates, which is not always achieved in basic ‘single read’ pathology studies. Once the gold 
standard is validated, careful thought must be applied to how these findings will be accurately co-registered with optical 
images, so as not to introduce further artefacts into the comparison between the novel technique and the gold standard. 
The different scales at which in vivo optical-image data is recorded and histopathological analysis is performed can make 
this particularly challenging167. 
Difficulties in conducting representative single-centre trials. To maximize opportunities for validation in multicentre 
trials, early-stage single-centre trials should replicate the common clinical environment as much as possible. First, 
representative populations should be chosen to reduce spectrum effects168. For example, due to the ethical 
considerations of taking biopsies from healthy tissue, many skin-imaging trials have been carried out in enriched 
populations with high disease incidence, which has prompted regulatory bodies to disregard such results and 
investigators to endorse the need for a mix of lesions representative of the target population, for the future testing of new 
approaches24. Second, standard operating procedures should be determined by a single centre and adhered to in 
multicentre trials in order to prevent bias. For example, inspecting images for minutes when the eventual standard 
operating procedure in a clinical setting would require inspection of videos in real time results in misleading performance 
evaluations147–150. If image data were collected according to an appropriate standard operating procedure, collation of 
	
data into an online repository would assist in the validation process for a new OIB. Third, the expertise of the operator 
and of the image interpreter should be representative of the expertise realistically available in routine care. Endoscopic 
trimodal imaging provides a cautionary example: promising results in a tertiary referral centre113 were not reproduced in a 
community practice setting111, which could have been due to a combination of spectrum effects, different standard 
operating procedures, or different expertise. 
 
Outlook 
Many of the OIBs reviewed here are still in development; and yet, several are already impacting patient care. Owing to 
their relatively low-cost implementation, lack of ionizing radiation, and potential for real-time analysis across a range of 
length scales, OIBs bring new opportunities for changing healthcare practice in the two case studies discussed in this 
Perspective as well as in many other areas169,170. 
Traditionally, the most advanced optical-imaging methods and almost all radiological-imaging methods have been 
confined to an expert setting, because of the expense and size of these devices and of the need of on-site expertise. The 
emergence of inexpensive and compact optical-detector technology and communications networks capable of 
broadcasting images means that image acquisition and interpretation no longer need to be co-localized. The 
development of cheap, robust and simple-to-use devices makes OIB data acquisition potentially feasible in primary care, 
for example with tethered capsule endoscopes or handheld skin-imaging devices17,129. In addition, the feasibility of image 
acquisition being performed in one centre, with experts interpreting images remotely, has already been demonstrated in 
endomicroscopy171. OIBs could, in future, be implemented in the home. The rapidly improving specifications of sensors 
within smartphones, the growing computational power of such devices, and their widespread access to mobile 
communication networks, have already led to applications for the monitoring of suspicious moles, but so far without 
proven accuracy or application value172. Data captured from smartphones could ultimately be interpreted remotely via 
expert-image interpreters or by using automated algorithms trained on the vast database of images resulting from such 
widespread acquisition. Examples of how these changes might impact the case studies discussed here are shown in Fig. 
3. 
We expect that this kind of flexible applications of OIBs will rapidly become more common in research. Remote image 
acquisition and interpretation in a range of indications and healthcare settings, from telepathology173 to 
teledermatology174, and from the home to specialist care, are likely to become increasingly widespread, enabling better 
patient triage and decreasing the costs associated with high-volume specialist-care imaging suites and with expert 
operators. Remote interpretation will allow for greater division of expertise, reducing training costs, and increasing the 
average expertise available for image analysis. For some indications, automated diagnosis trained on centralized image 
databases might circumvent the need for an image interpreter entirely. 
There are a number of challenges for advancing the clinical implementation of OIBs. Regulatory approvals for new 
optical-imaging devices tend to favour commercial vendors rather than clinical value135, and often procedures are 
approved with a new device where the application is not improving care but rather just changing the sub-specialty that 
implements the procedure. Commercially, devices may be approved on the basis of similarity to a predicate device, 
without proof of clinical utility135. Without optical-imaging standardization, similarity to a predicate may be difficult to 
define. Worse still is the prospect that the predicate itself may pre-date current regulations. Since devices can be 
marketed without proof of clinical utility, manufacturers may lack the motivation to invest the significant time, money and 
expertise required to conduct trials for assessing clinical utility, despite the potential long-term benefits. 
Distributing devices into the hands of the patients themselves raises questions about the appropriate nature of clinical 
trials for testing, and brings additional challenges in standardization. Although the individual optical hardware or software 
may itself be inexpensive, the final clinical test must fully represent the cost of development, meaning that the cost-per-
test can in some cases be similar to or greater than the costs of the existing standard of care. 
The advent of new liquid biomarkers has raised questions about the future utility of imaging in the context of early cancer 
detection. Imaging currently provides crucial insight for the early detection of malignant melanoma and oesophageal 
cancer, and endoscopy methods are also broadly applied for the identification of cancers in the aerodigestive tract, as 
well as in the cervix and bladder. Although liquid biomarkers have shown great promise, even a study175 that achieved 
good performance for the detection of late-stage cancers (73% sensitivity) reported much poorer performance for the 
detection of early-stage disease (40% median sensitivity in the eight cancers tested, and only 20% sensitivity in 
oesophageal cancer). Moreover, although liquid biomarkers have the potential to accurately detect and even localize 
early-stage disease, imaging is likely to remain an important tool in screening and surveillance programmes for early 
cancer detection for many years to come. Also, imaging is the only test capable of providing the detailed spatially 
resolved information that is ultimately required for the resection of early cancers, and has shown great promise in this 
regard176,177. It is therefore likely that liquid biomarkers could be implemented as tools complementary to imaging, 
perhaps as a low-cost early-stage option to pre-screen patients prior to imaging, should a sufficiently high specificity be 
achieved. 
Advanced optical-imaging research requires the technical development of optical devices as well as the technical and 
biological validation of the resulting OIBs. In many cases, the discovery of promising OIBs using optical devices 
dedicated to ex vivo imaging can motivate the development of devices able to measure the same biomarker in vivo. An 
understanding of the strengths and weaknesses of these optical devices is needed to assess the feasibility of measuring 
certain biomarkers in a clinical scenario, with a clear appreciation for the biological heterogeneity of the biomarker. For 
example, it may be the case that a multimodal approach is needed to achieve the required performance through the 
combination of two or more OIBs (ref. 178). These aspects demand a multidisciplinary research effort that combines 
	
clinical expertise of an unmet need with physics and engineering knowledge of the optical interactions in order to 
specifically tailor devices for the detection of known biomarkers. The sharing of intellectual-property ownership, or of 
appropriate licencing agreements, may also be required in order to combine imaging modalities. Furthermore, 
collaboration with computer scientists may help to better the design of interpretation algorithms to yield useful clinical 
biomarkers. Embracing this multidisciplinary approach is necessary to promote the translation of OIBs. 
Imaging is currently the only medical tool capable of providing detailed, immediate and spatially resolved biological 
information in vivo, which is especially relevant for the diagnosis of the earliest stages of cancer. Despite these promises, 
few OIBs have been translated to routine clinical use. The translational characteristics and barriers discussed here 
complement the OIB roadmap, which we hope will improve the chances of new optical-imaging approaches achieving 
widespread clinical implementation. The vast array of complex tissue–light interactions and the equally diverse arsenal of 
optical devices for detecting these interactions should help to improve the current standard-of-care for cancer patients. 
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Fig. 1 | Visible and near-infrared light–tissue interactions. Visible and near-infrared light experiences a wide range of 
complex interactions with tissue constituents. OIBs exploit these interactions in clinical applications. The interactions 
illustrated are: reflection, absorption and scattering (occurring, for example, in white-light imaging, diffuse reflectance 
spectroscopy, elastic scattering spectroscopy, narrow-band imaging, and multispectral or hyperspectral imaging), phase 
(in, for example, OCT and angle-resolved low-coherence interferometry), polarization (in, for example, polarimetry and 
holography), nonlinear effects (in Raman spectroscopy, coherent anti-stokes Raman spectroscopy, multiphoton 
fluorescence imaging and multi-harmonic generation imaging), fluorescence (in autofluorescence intensity or lifetime 
imaging of endogenous fluorophores, and in optical molecular imaging of exogenous fluorophores), and the 
photoacoustic effect (in photoacoustic, or optoacoustic, microscopy and tomography). Line colours represent 
wavelengths of light. Multicoloured lines represent broadband light. Changes in colour represent changes in wavelength 
when light interacts with tissue. Perpendicular lines represent wavefronts and thus indicate the optical coherence of 
phase. Arrowed perpendicular lines represent the orientation of polarization. Curved lines represent the emission of 
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Fig. 2 | Roadmap for OIBs. The proposed roadmap differs from the radiological-imaging-biomarker roadmap3 by 
considering the intrinsic coupling of OIBs to the development of the optical-imaging modality. Red feedback loops 
decelerate clinical translation. Purple circles represent points at which careful consideration of translational 
characteristics (1–6) can accelerate translation. Technical and biological validations occur in parallel, and are closely 
linked because of the interplay between device, operator, interpreter and OIB. The technical validation occurs throughout 
the roadmap to ensure availability and precision in all settings. Cost effectiveness is omitted here yet it impacts the 
roadmap at every stage, owing to the equipment and personnel costs of performing imaging studies3. Translational 
characteristics: (1) contrast mechanism, (2) instrumentation, (3) operator expertise, (4) image-interpreter expertise, (5) 
repeatability and reproducibility, and (6) co-registration. SOP, standard operating procedure. 
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Fig. 3 | Current and potential future clinical implementations of optical imaging in two case studies. The current 
clinical pipeline (black arrows) from the home through primary care to specialist care is shown for patients with 
suspected Barrett’s oesophagus (green) and suspicious malignant melanoma (pink). The potential future pipelines (red 
lines) will be mediated by new or modified indications for imaging (red boxes) and high-speed communication networks 
(red dashed lines). Risk stratification in primary care reduces the number of false positives referred for urgent specialist 
follow-up. Boxes highlight where imaging takes place in the pipeline. 
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Table 1 | Optical-imaging modalities, and selected OIBs currently in development for early cancer detection. 
 
Approach Source of contrast Biological change in cancer Example of OIB 
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